Prudential Financial
CDAK

Prudential Financial’s Codiak BioSciences, Inc. Common Stock CDAK Stock Holding History

Prudential Financial’s Portfolio CDAK Stock Details CDAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-47,800
Closed -$19K – 2699
2022
Q4 		$19K Buy
47,800
+11,200
+31% +$7.37K ﹤0.01% 2569
2022
Q3 		$29K Buy
+36,600
New +$76.8K ﹤0.01% 2608

Other funds holding CDAK

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
UOTTAIMCU
University of Texas/Texas AM Investment Management Co (UTIMCO) Austin, Texas $687M AUM 21.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
FA
Forefront Analytics West Conshohocken, Pennsylvania $110M AUM 18.54% 1-Year Est. Return
PM
Parametrica Management Wanchai, Hong Kong $88M AUM 48.84% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Prudential Financial's CDAK Position: Q1 2023 in Review

Prudential Financial sold out of Codiak BioSciences, Inc. Common Stock (CDAK) in Q1 2023, closing a stake of 47,800 shares — an estimated $19K sold.

Prudential Financial first reported a position in CDAK in Q3 2022 and held it in 2 quarters. The position peaked at $29K in Q3 2022. 27 funds tracked by Wall St. Rank hold CDAK as of Q1 2023.

  • Prudential Financial reported no remaining Codiak BioSciences, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Prudential Financial sold 47,800 Codiak BioSciences, Inc. Common Stock shares in Q1 2023, an estimated $19K.
  • Prudential Financial first reported a position in Codiak BioSciences, Inc. Common Stock in Q3 2022 and held it in 2 quarters.
  • Prudential Financial's Codiak BioSciences, Inc. Common Stock position peaked at $29K in Q3 2022.
  • 27 funds tracked by Wall St. Rank held Codiak BioSciences, Inc. Common Stock as of Q1 2023.

Based on Prudential Financial's 13F filing for Q1 2023, filed 12 May 2023.